Peptide vaccination using nonionic block copolymers induces protective anti-viral CTL responses

Vaccine

Volumn 18, Issue 5-6, 1999, Pages 549-557

  Gibson Lanier, J ^a   Newman, Mark J ^b   Lee, Eushin M ^b   Sette, Alessandro ^c   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Vaxcel Inc   (United States)

^c Epimmune   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CD8 ANTIGEN; COPOLYMER; FREUND ADJUVANT; GAMMA INTERFERON; SYNTHETIC PEPTIDE; VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; EMULSION; FEMALE; IN VITRO STUDY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; EMULSIONS; FEMALE; INTERFERON TYPE II; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED BALB C; NUCLEOCAPSID PROTEINS; NUCLEOPROTEINS; PEPTIDE FRAGMENTS; POLYMERS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VIRAL CORE PROTEINS; VIRAL VACCINES;

EID: 0032883107     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00220-0     Document Type: Article

References (47)

1. Newman M.J., Powell M.F. Immunological and formulation design considerations for subunit vaccines. Powell M.F., Newman M.J. Vaccine design: the subunit and adjuvant approach. 1995;1 Plenum Press, New York.
2. Hilleman M.R. Critical appraisal of emulsified oil adjuvants applied to viral vaccines. Prog. Med. Virol. 8:1966;131-182.
3. Kimura J., Nariuchi H., Watanbe T., Matuhasi T., Okayasu I., Hatakeyama S. Studies on the adjuvant effect of water-in-oil-in-water emulsion in sesame oil. I. Enhanced and persistent antibody formation by antigen incorporation into the water-in-oil-in-water emulsion. Jpn. J. Exp. Med. 48:1978;149-154.
4. Brugh M., Stone H.D., Lipton H.W. Comparison of inactivated Newcastle Disease viral vaccines containing different emulsion adjuvants. Am. J. Vet. Res. 44:1983;72-75.
5. Singh M., Hioe C., Qiu H., Li X-M., Wang C.Y., Koff W., Zamb T., Nixon D.F. CTL induction using synthetic peptides delivered in emulsions- critical role of the formulation procedure. Vaccine. 15:1997;1773-1778.
6. Newman M.J., Balusubramanian M., Todd C.W. Development of adjuvant-active nonionic block copolymers. Adv. Drug Deliv. Rev. 32:1998;199-223.
7. Barr I.G., Sjolander A., Cox J.C. ISCOMs and other saponin based adjuvants. Adv. Drug Deliv. Rev. 32:1998;247-271.
8. Howerton D.A., Hunter R.L., Ziegler H.K., Check I.J. The induction of macrophage Ia expression in vivo by synthetic copolymer L81. J. Immunol. 144:1990;1578-1584.
9. Hunter R.L., Bennett B. The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblocks and octablock copolymers. J. Immunol. 133:1984;3167-3175.
10. Todd C.W., Pozzi L-A.M., Guarnaccia J.R., Balasubramanian M., Henk W.G., Younger L.E., Newman M.J. Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccine formulations. Vaccine. 15:1997;564-570.
11. van der Most R.G., Sette A., Oseroff C., Alexander J., Murali-Krishna K., Lau L.L., Southwood S., Sidney J., Chesnut R.W., Matloubian M., Ahmed R. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic Lymphocytic Choriomeningitis Virus Infection. J. Immunol. 157:1996;5543-5554.
12. Carbone F.R., Bevan M.J. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J. Exp. Med. 169:1989;603-612.
13. Aichele P., Hengartner H., Zinkernagel R.M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J. Exp. Med. 171:1990;1815-1820.
14. Kast W.M., Roux L., Curren J., Blom H.J.J., Voordouw A.C., Meloen R.H., Kolakofsky D., Melief C.J.M. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA. 88:1991;2283-2287.
15. Brown F. The potential of peptides as vaccines. Semin. Virol. 1:1990;67-74.
16. Shulz M., Zinkernagel R.M., Hengartner H. Peptide-induced antiviral protection by cytotoxic T-cells. Proc. Natl. Acad. Sci. USA. 88:1991;991-993.
17. Ahmed R., Jamieson B., Porter D.D. Immune therapy of a persistent and disseminated viral infection. J. Virol. 61:1987;3920-3929.
18. Byrne J.A., Oldstone M.B.A. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J. Virol. 51:1984;682-686.
19. + T cells and nonspecific bone marrow-derived cells. J. Virol. 61:1987;3930-3937.
20. + T lymphocytes mediate clearance of virus and regulate the antiviral antibody response. J. Virol. 61:1987;1867-1874.
21. Murali-Krishna K., Altman J.D., Suresh M., Sourdive D.J.D., Zajac A.J., Miller J.D., Slansky J., Ahmed R. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 8:1998;177-187.
22. Battegay M., Moskophidis D., Rahemtulla A., Hengartner H., Mak T.W., Zinkernagel R.M. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J. Virol. 68:1994;4700-4704.
23. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:1994;8056-8065.
24. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J.D., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188:1998;2205-2213.
25. Ahmed R., Salmi A., Butler L.D., Chiller J., Oldstone M.B.A. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice: role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160:1984;521-540.
26. Whitton J., Tishon A., Lewicki H., Gephard J., Cook T., Salvato M., Joly E., Oldstone M.B.A. Molecular analysis of a five amino acid cytotoxic t-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. J. Virol. 63:1989;4303-4310.
27. Shulz M., Aichele P., Schneider R., Hansen T.H., Zinkernagel R.M., Hengartner H. Major histocompatibility complex binding and T-cell recognition of a viral nonpeptide containing a minimal tetrapeptide. Eur. J. Immunol. 21:1991;1181-1185.
28. King C.C., de Fries R., Kolhekar S.R., Ahmed R. In vivo selection of lymphocyte-tropic and macrophage-tropic variants of lymphocytic choriomeningitis virus during persistent infection. J. Virol. 64:1990;5611-5616.
29. Ahmed R., Hahn C.S., Somasundaram T., Villarete L., Matloubian M., Strauss J.H. Molecular basis of organ-specific selection of viral variants during chronic infection. J. Virol. 65:1991;4242-4247.
30. Matloubian M., Kolhekar S.R., Somasundaram T., Ahmed R. Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus. J. Virol. 67:1993;7340-7349.
31. Ahmed R., Oldstone M.B.A. Organ-specific selection of viral variants during chronic infection. J. Exp. Med. 167:1988;1719-1724.
32. Ruppert J., Sidney J., Calls E., Kubo R.T., Grey H.M., Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell. 74:1993;929-937.
33. Lundsted L.G., Schmolka I.R. The synthesis and properties of block copolymer surfactants. Ceresa R.J. Block and Graft Copolymerization. 1976;1 Wiley, New York.
34. St. Pierre L.E. Polymers from 1,2 epoxides: I. Chemistry. Gaylord N.G. Polyethers. 1963;83 Interscience Publishers, New York.
35. Kastens A.S. Polymers from 1,2 epoxides. II. Chemistry. applications and technologies. Gaylord N.G. Polyethers. 1963;169 Interscience Publishers, New York.
36. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., Yaun L., Chisari F.V., Furze J., Bartholemeuz R., Chesnut R.W. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95:1995;341-349.
37. Townsend A.R., Routhbard J., Gotch F.M., Bahadur G., Wraith D., McMichael A.J. The epitopes of influenza virus nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 44:1986;959-968.
38. Czerkinski C.C., Nilsson L.A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody secreting cells. J. Immunol. Meth. 65:1983;109-121.
39. Taguchi T., McGhee J.R., Coffman R.L., Beagley K.W., Eldridge J.H., Takatsu K., Kiyono H. Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. J. Immunol. Meth. 128:1990;65-73.
40. Newman M.J., Todd C.W., Lee E.M., Balasubramanian M., Didier P.J., Katz J.M. Increasing the immunogenicity of a trivalent influenza virus vaccine with adjuvant-active nonionic block copolymers for potential use in the elderly. Mech. Aging Dev. 93:1997;189-203.
41. Triozzi P.L., Stevens V.C., Aldrich W., Powell J., Todd C.W., Newman M.J. Effects of a β-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advanced cancer. Clin. Cancer Res. 3:1997;2355-2363.
42. Ke Y., McGraw C.L., Hunter R.L., Kapp J.A. Nonionic triblock copolymers facilitate delivery of exogenous proteins into the MHC class I and class II processing pathways. Cell. Immunol. 176:1997;113-121.
43. Koup R.A., Pikora C.A., Luzunaga K., Brettler D.B., Day E.S., Mazzara G.P., Sullivan J.L. Temporal association of cellular immune responses with the initial control of viremia in primary HIV 1 syndrome. J. Virol. 68:1994;4650-4655.
44. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., Oldstone M.B.A. Virus specific CD8+ cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68:1994;6103-6110.
45. Herbert W.J. Multiple emulsions. A new form of mineral-oil antigen adjuvant. Lancet. 2:1965;771.
46. Taylor P.J., Miller C.L., Pollock T.M., Perkins F.T., Westwood M.A. Antibody response and reactions to aqueous influenza vaccine, simple emulsion vaccine. A report to the Medical Research Council Committee on influenza and other respiratory virus vaccines. J. Hyg. 67:1969;485-490.
47. Freestone D.S., Hamilton-Smith S., Schild G.C., Buckland R., Chinn S., Tyrrell D.A. Antibody responses and resistance to challenge in volunteers vaccinated with live attenuated, detergent split and oil adjuvant A2-Hong Kong-68 (H 3 N 2) influenza vaccines. A report to the Medical Research Council Committee on Influenza and other respiratory virus vaccines. J. Hyg. 70:1972;531-543.